Amylyx Pharmaceuticals Advances Pipeline Programs in 2026

Amylyx Pharmaceuticals (NASDAQ: AMLX) is gaining attention as multiple pipeline programs approach key clinical milestones. The Phase 3 trial for Avexitide, targeting post-bariatric hypoglycemia, has completed enrollment with topline results expected in Q3 2026.

By Chris Markoch, MarketBeat Sun, May 24, 2026 at 3:50 PM GMT+3 5 min read · Yahoo Finance · May 24, 2026, 12:50 UTC

Amylyx Pharmaceuticals Advances Pipeline Programs in 2026

Tickers: $AMLX $MRK $REGN

Topics: Avexitide biotech pipeline progress post-bariatric hypoglycemia

Read the full article at Yahoo Finance

More World news

Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC
U.S. Trade Representative Jamieson Greer to Discuss Tariff Policies and Export Controls CNBC · November 12, 2026, 13:31 UTC
Coinbase CEO Brian Armstrong Discusses Binance Hack and Political Shifts Impacting Crypto CNBC · November 12, 2026, 13:44 UTC
Tradeify Announces Multi-Year Partnership with Inter Miami CF PR Newswire · November 12, 2026, 14:15 UTC